Skip to main content

Health condition

Atypical hyperplasia, the pre-cancer signal in breast, womb and prostate.

Not cancer, not benign. A specialist plan turns an uncertain biopsy result into clear next steps and a personalised risk conversation.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Editorial team

    Written by our editorial team from the UK sources listed on each page.

  • 02

    Sourced from guidance

    Checked against NICE, RCOG, BAUS, ABS and peer-reviewed sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK pathways for ADH, ALH, endometrial intraepithelial neoplasia, ASAP and HGPIN.

Key facts

Atypical hyperplasia at a glance.

The essentials, in plain English. Where atypia is found, what it means for your risk, and how UK specialists respond.

  • What it is

    A hub term for pre-malignant cellular changes in breast, endometrium and prostate. Not cancer, but a signal to investigate and act.

  • Breast (ADH and ALH)

    Atypical ductal hyperplasia carries a 4 to 5 times risk of breast cancer in either breast. Atypical lobular hyperplasia carries roughly 4 times.

  • Endometrium (AH/EIN)

    Atypical endometrial hyperplasia (endometrial intraepithelial neoplasia) sits alongside invasive cancer in up to 40% of hysterectomy specimens.

  • Prostate (ASAP/HGPIN)

    Atypical small acinar proliferation is followed by cancer on repeat biopsy in 40 to 50% of men. HGPIN raises subsequent cancer risk.

  • Why it matters

    Every form deserves a specialist plan. The right test, the right timing and the right risk conversation change outcomes.

  • Family history

    BRCA1, BRCA2, PALB2, CHEK2, ATM and Lynch syndrome can shape both the diagnosis and the management plan.

Why this guide matters

A pre-cancer diagnosis is a pivot point.

Atypia is a chance to act early. The three points below shape everything else on this page and every UK MDT decision.

  • It changes your future risk

    Breast, endometrial and prostate atypia all raise the chance of a future cancer. Knowing the number turns worry into a plan.

  • It can sit next to invasive cancer

    Up to a third of breast ADH and up to 40% of endometrial atypia sits next to already invasive disease at surgery.

  • There are real options

    Enhanced screening, chemoprevention, hormonal treatment, fertility-sparing therapy and, when needed, risk-reducing surgery.

How the diagnosis is made

From first finding to a clear plan.

The steps a UK breast, gynaecology or urology team will normally follow, in order, so you know what to expect and why.

  1. 01

    Assessing

    Screening or symptom trigger

    Most breast atypia is picked up on a screening mammogram. Endometrial atypia usually presents with postmenopausal or heavy irregular bleeding. Prostate atypia is a biopsy finding.

  2. 02

    Assessing

    First-line imaging

    Diagnostic mammogram and ultrasound for breast changes. Transvaginal ultrasound for endometrial thickness. Multiparametric MRI for a suspicious prostate.

  3. 03

    Assessing

    Tissue sampling

    Core needle biopsy for the breast. Pipelle biopsy or hysteroscopy-directed sampling for the endometrium. TRUS or MRI-fusion biopsy for the prostate.

  4. 04

    Confirming

    Expert histopathology

    A specialist pathology review, and a second opinion where indicated, distinguishes atypia from carcinoma in situ and invasive disease.

  5. 05

    Confirming

    Multidisciplinary review

    A breast, gynaecology or urology MDT agrees the next step so imaging, pathology and clinical picture line up.

  6. 06

    Preparing

    Surgical excision or staging

    Vacuum-assisted or open excision confirms breast atypia and rules out concurrent cancer. Pelvic MRI may stage the endometrium before hysterectomy.

  7. 07

    Preparing

    Genetics and risk assessment

    Tools such as IBIS, Gail or Tyrer-Cuzick model breast risk. Family history triggers BRCA, PALB2, CHEK2, ATM or Lynch syndrome testing where appropriate.

Typical timeline: weeks from suspicious result to an agreed plan.

Symptoms

What atypical hyperplasia actually looks like.

Most breast and prostate atypia is silent and picked up on imaging or biopsy. Endometrial atypia usually shows itself as bleeding.

  • Screening mammogram change

    New microcalcifications or an evolving density on routine screening. Almost always painless and only visible on imaging.

  • Postmenopausal bleeding

    Any bleeding after the menopause needs urgent gynaecology assessment. Endometrial atypia is a leading treatable cause.

  • Heavy or irregular perimenopausal bleeding

    Prolonged, heavy or unpredictable bleeding around the menopause deserves an endometrial biopsy, especially with PCOS or high BMI.

  • Rising or borderline PSA

    A raised or rising prostate-specific antigen may lead to MRI and biopsy, where ASAP or HGPIN can be found.

  • Incidental biopsy finding

    Atypia is often reported on a biopsy taken for another reason. It is not cancer, but it changes the follow-up plan.

  • Hormonal drivers

    Unopposed oestrogen, obesity, PCOS, late menopause and long-term tamoxifen all raise endometrial risk.

  • Family history pattern

    Breast, ovarian, prostate, pancreatic or bowel cancer in close relatives changes risk and may trigger genetic testing.

  • Red flag - concurrent cancer

    Up to a third of breast ADH and up to 40% of endometrial atypia sits next to an already invasive cancer.

Treatment

How atypia is treated in the UK.

Breast excision and enhanced screening, chemoprevention where indicated, hysterectomy or fertility-sparing hormones for the endometrium, and repeat imaging for the prostate.

  • Breast ADH - surgical excision

    Percutaneous ADH is usually excised (vacuum-assisted or open) to exclude concurrent DCIS or invasive cancer, then followed with imaging.

  • Breast ALH - excision or surveillance

    Excision is often offered when imaging and pathology do not match. Some lower-risk ALH is managed with close surveillance after MDT review.

  • Enhanced breast screening

    Annual mammography, with breast MRI in selected higher-risk women, replaces routine three-yearly screening after an atypia diagnosis.

  • Chemoprevention

    Tamoxifen for 5 years pre-menopause, or anastrozole/exemestane post-menopause, is offered under NICE CG164 to reduce future breast cancer risk.

  • Risk-reducing mastectomy

    Selective option for women with BRCA1/2 or a very strong family history combined with atypia. Always a shared, MDT-led decision.

  • Hysterectomy with BSO

    Total hysterectomy and bilateral salpingo-oophorectomy is the definitive treatment for endometrial atypia after the menopause or when family is complete.

  • Fertility-sparing progestin therapy

    For younger women wanting pregnancy, high-dose oral progestin (megestrol, medroxyprogesterone) or a levonorgestrel intrauterine system achieves regression in around 85%.

  • Prostate active surveillance

    ASAP and isolated HGPIN are not treated with surgery or radiotherapy. Multiparametric MRI and repeat targeted biopsy guide the pathway.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your specialist knows your imaging, pathology and family history and can tell you which parts apply to you. If in doubt, ask for the MDT view.

  • NICE CG164. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer.

  • NICE NG12. Suspected cancer: recognition and referral (2-week-wait pathways for breast, gynaecology and urology).

  • RCOG/BSGE Green-top Guideline No. 67. Management of Endometrial Hyperplasia.

  • Association of Breast Surgery (ABS). Best practice guidelines for the management of B3 lesions.

  • British Association of Urological Surgeons (BAUS). Guidance on ASAP, HGPIN and prostate biopsy pathways.

Red flags

When atypia needs urgent attention.

Most atypia is managed on a planned specialist pathway. These are the situations that need to be brought forward.

  • Postmenopausal bleeding

    Any vaginal bleeding after the menopause needs urgent gynaecology review under the 2-week-wait pathway. Endometrial atypia and cancer are the main concerns.

  • Discordant breast imaging

    When imaging looks worse than the biopsy suggests, or upgrade on excision is likely, the MDT should reassess quickly.

  • Rapidly rising PSA

    A rapid PSA rise with prior ASAP or HGPIN needs prompt MRI and repeat targeted biopsy rather than routine surveillance.

  • Strong family history

    Multiple close relatives with breast, ovarian, prostate, pancreatic or bowel cancer should trigger genetic assessment.

  • Lynch syndrome features

    Endometrial atypia in a woman with a Lynch pattern deserves early genetics referral and consideration of risk-reducing surgery.

  • Persistent bleeding on progestin

    Ongoing bleeding, or failure to regress on repeat sampling at 6 months, tips the balance toward hysterectomy.

  • Obesity and unopposed oestrogen

    Modifiable drivers of endometrial atypia. A weight and hormone review is part of every treatment plan.

  • Tamoxifen-related bleeding

    Any abnormal bleeding on tamoxifen needs prompt endometrial assessment. Tamoxifen raises endometrial risk.

  • Concurrent invasive cancer

    A significant minority of atypia diagnoses hide an already invasive cancer. Excision, hysterectomy or repeat biopsy is often the safest next step.

Living with it

A pre-cancer diagnosis, with a clear plan.

Four things that make the biggest difference year to year. Know your risk number, stick to enhanced screening, address modifiable drivers and use your specialist nurse.

A quiet reminder

A finding is not a fate.

Most people with atypical hyperplasia never develop cancer. The plan is designed to catch change early, and to lower the odds.

  1. 01 Plan

    Know your risk number

    Ask for your 10-year and lifetime risk using IBIS or Tyrer-Cuzick. A number turns worry into a plan.

  2. 02 Screening

    Stick to enhanced surveillance

    Annual mammography, and MRI when advised, catches change early. Book the next scan before you leave the last one.

  3. 03 Lifestyle

    Weight, alcohol and hormones

    Weight loss, moderating alcohol and reviewing hormone therapy modestly lower breast and endometrial risk over time.

  4. 04 Support

    Use your specialist nurse

    A breast, gynaecology or urology clinical nurse specialist is there for questions between appointments. Use them.

Frequently asked

Everything we get asked about atypical hyperplasia.

Quick answers on risk, surgery, fertility-sparing options and prostate follow-up.

  • Is atypical hyperplasia the same as cancer?

    No. Atypical hyperplasia sits on the spectrum between benign change and cancer. It is a pre-malignant finding that raises your future risk and, in some cases, sits next to an already invasive cancer, which is why further tests and specialist review matter.

  • How much does breast ADH or ALH raise my cancer risk?

    Atypical ductal hyperplasia carries around a 4 to 5 times higher risk of breast cancer in either breast over the following decades. Atypical lobular hyperplasia carries roughly 4 times. Lobular carcinoma in situ, which is separate, sits higher at 8 to 10 times. Your personal number depends on age, family history and other risk factors.

  • Why do I need surgery if it is not cancer?

    When atypical ductal hyperplasia is found on a needle biopsy, 15 to 30% of women turn out to have DCIS or invasive cancer at excision. Removing the area confirms the diagnosis and rules out concurrent cancer. The threshold for excising atypical lobular hyperplasia is lower and often discussed at MDT.

  • Can I keep my womb if I have endometrial atypia?

    Sometimes. For younger women wanting pregnancy, fertility-sparing treatment with high-dose oral progestin or a levonorgestrel intrauterine system achieves regression in around 85%, with repeat sampling every 3 to 6 months. Hysterectomy is usually offered once the family is complete or after the menopause because up to 40% of atypia sits alongside invasive cancer.

  • What does ASAP or HGPIN on a prostate biopsy mean?

    Atypical small acinar proliferation is a suspicious cluster of cells that the pathologist cannot definitely call cancer. It is followed by cancer on repeat biopsy in 40 to 50% of men. HGPIN also raises subsequent cancer risk. Both usually mean a repeat multiparametric MRI and targeted biopsy rather than treatment.

  • Should I have genetic testing?

    A strong family history of breast, ovarian, prostate, pancreatic or bowel cancer, or a Lynch pattern, should trigger a referral for genetic counselling. Panels typically look at BRCA1, BRCA2, PALB2, CHEK2, ATM and the Lynch genes, and the result can shape both your surveillance and any risk-reducing surgery.

Related content

Keep reading.